nimesulide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1935 | 51803-78-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 2 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 9.27 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1985 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Renal failure neonatal | 108.35 | 55.04 | 12 | 175 | 38 | 2357860 |
| Neonatal respiratory acidosis | 83.50 | 55.04 | 9 | 178 | 20 | 2357878 |
| Ductus arteriosus stenosis foetal | 82.90 | 55.04 | 9 | 178 | 22 | 2357876 |
| Abdominal pain upper | 78.81 | 55.04 | 22 | 165 | 22078 | 2335820 |
| Drug abuse | 66.57 | 55.04 | 17 | 170 | 12009 | 2345889 |
| Bradycardia neonatal | 66.45 | 55.04 | 9 | 178 | 184 | 2357714 |
| Cyanosis neonatal | 64.75 | 55.04 | 8 | 179 | 76 | 2357822 |
| Premature baby | 64.41 | 55.04 | 13 | 174 | 3191 | 2354707 |
| Neonatal respiratory distress syndrome | 64.12 | 55.04 | 10 | 177 | 558 | 2357340 |
| Intentional self-injury | 55.43 | 55.04 | 12 | 175 | 4115 | 2353783 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Mixed liver injury | 63.16 | 58.93 | 9 | 108 | 264 | 1746400 |
| Face oedema | 62.08 | 58.93 | 12 | 105 | 2324 | 1744340 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M01AX17 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Other antiinflammatory and antirheumatic agents, non-steroids |
| ATC | M02AA26 | MUSCULO-SKELETAL SYSTEM TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN Antiinflammatory preparations, non-steroids for topical use |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D016861 | Cyclooxygenase Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
Drug Use (View source of the data)
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.03 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium-dependent dopamine transporter | Transporter | Ki | 4.93 | DRUG MATRIX | |||||
| Interstitial collagenase | Enzyme | IC50 | 4.63 | DRUG MATRIX | |||||
| Myeloperoxidase | Enzyme | IC50 | 5.68 | CHEMBL | |||||
| Prostaglandin G/H synthase 1 | Enzyme | IC50 | 5.42 | CHEMBL | |||||
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Enzyme | IC50 | 5.70 | WOMBAT-PK | |||||
| Prostaglandin G/H synthase 2 | Enzyme | IC50 | 5.91 | WOMBAT-PK | |||||
| Aromatase | Enzyme | IC50 | 4.57 | WOMBAT-PK | |||||
| Prostaglandin G/H synthase 1 | Enzyme | IC50 | 5.21 | CHEMBL | |||||
| Prostaglandin G/H synthase 2 | Enzyme | IC50 | 6.40 | CHEMBL | |||||
| Sodium-dependent neutral amino acid transporter B(0)AT1 | Unclassified | INHIBITOR | IC50 | 4.64 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| C0132515 | UMLSCUI |
| D01049 | KEGG_DRUG |
| 703480002 | SNOMEDCT_US |
| 004182 | NDDF |
| 53694 | RXNORM |
| 703479000 | SNOMEDCT_US |
| CHEMBL56367 | ChEMBL_ID |
| V4TKW1454M | UNII |
| 4885 | INN_ID |
| NIM | PDB_CHEM_ID |
| DB04743 | DRUGBANK_ID |
| CHEBI:44445 | CHEBI |
| 4495 | PUBCHEM_CID |
| 7401 | IUPHAR_LIGAND_ID |
| C012655 | MESH_SUPPLEMENTAL_RECORD_UI |
Pharmaceutical products:
None